Results 31 to 40 of about 512,435 (267)

Urachal Adenocarcinoma

open access: yesThe Annals of African Surgery, 2013
Urachal adenocarcinoma is a rare tumor and represents 0.17–0.34% of all bladder tumors. Most of the reported cases are in western literature and to the best of our knowledge this is the first case report of urachal adenocarcinoma in sub-Saharan Africa ...
s nguku   +3 more
doaj  

Lung adenocarcinoma with mixed solid and crazy‐paving appearances

open access: yesClinical Case Reports, 2021
“Crazy paving” on CT images refers to the superimposition of ground‐glass opacity and linear pattern resembling irregularly shaped paving stones. Initially, “crazy paving” was described as a pathognomonic sign of alveolar proteinosis.
Roqiah Fatmawati Abdul Kadir   +3 more
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Unexpected Histopathological Diagnoses in Acute Appendicitis Specimens: A Retrospective Analysis of 2076 Patients

open access: yesTurkish Journal of Colorectal Disease, 2020
Aim:Acute appendicitis is the most common cause of emergency abdominal surgery in the world. Although the etiology of appendicitis is still not fully known, possible causes include lumen obstruction.
Ufuk Uylaş   +4 more
doaj   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

open access: yesMolecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner   +14 more
wiley   +1 more source

Esophageal Carcinoma and Associated Risk Factors: A Case-control Study in Two Tertiary Care Hospitals of Kabul, Afghanistan

open access: yesCancer Management and Research, 2022
Ramin Saadaat,1 Jamshid Abdul-Ghafar,1 Ahmed Maseh Haidary,1 Nooria Atta,2 Tazeen Saeed Ali3 1Department of Pathology and Clinical Laboratory, French Medical Institute for Mothers and Children (FMIC), Kabul, Afghanistan; 2Department of Gynecology and ...
Saadaat R   +4 more
doaj  

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

open access: yesMolecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena   +15 more
wiley   +1 more source

Adenocarcinoma do saco endolinfático: relato de caso

open access: yesArquivos de Neuro-Psiquiatria, 2002
Apresenta-se um caso de adenocarcinoma do saco endolinfático e revê-se a literatura. O quadro clínico manifestou-se por tonteira e perda progressiva da audição consequentes a tumor do saco endolinfático.
Silveira Roberto Leal   +3 more
doaj  

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

open access: yesMolecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen   +9 more
wiley   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy